Abbott Laboratories (ABT) Stock Analysis
Verdict: WATCH (do not buy)
Exact Sciences integration and the 2027 Nutrition spin-off unlock high-margin medtech upside, but $32.6B debt and EPS dilution constrain near-term returns.
Investment score: 58/100
Analysis as of
Is Abbott Laboratories stock worth reviewing? The TradeMates thesis
The model sees Abbott as a high-quality medtech giant undergoing a significant structural transition. The acquisition of Exact Sciences ($21B equity value) and the announced October 2026 tax-free spin-off of the Nutrition division by late 2027 position Abbott as a higher-margin medtech pure play. However, near-term upside is capped by debt leverage ($32.60B total debt) and M&A dilution.
7-factor investment score
- Valuation: 62/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 58/100 (weight 15%)
- Earnings Quality: 52/100 (weight 15%)
- Insider Sentiment: 42/100 (weight 10%)
- Analyst Consensus: 78/100 (weight 10%)
- Risk-Adjusted Return: 62/100 (weight 15%)
Abbott Laboratories opportunities and risks
What speaks for ABT
- Exact Sciences Cancer Diagnostics Platform Expansion
What speaks against ABT
- Debt Burden and EPS Dilution from Exact Sciences Acquisition
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ABT | 38.0x | 3.7x | 21.1x | 57.1% | 9.7% | 4.9% |
| ISRG | 52.7x | 13.5x | 35.5x | 67.2% | 25.5% | 2.3% |
| SYK | 31.4x | 4.5x | 19.3x | 65.2% | 14.4% | 4.0% |
| BSX | 18.5x | 3.2x | 13.5x | 71.2% | 17.5% | 5.5% |
| BDX | 59.7x | 2.6x | 15.7x | 46.1% | 4.5% | 4.8% |
| EW | 51.2x | 7.9x | 31.1x | 78.0% | 15.4% | 2.8% |
| Peer median | 51.2x | 4.5x | 19.3x | 67.2% | 15.4% | 4.0% |
Frequently asked questions about Abbott Laboratories (ABT)
Is ABT stock a good investment?
The TradeMates model rates Abbott Laboratories as WATCH (do not buy) with an investment score of 58/100. The model sees Abbott as a high-quality medtech giant undergoing a significant structural transition. The acquisition of Exact Sciences ($21B equity value) and the announced October 2026 tax-free spin-off of the Nutrition division by late 2027 position Abbott as a higher-margin medtech pure play. However, near-term upside is capped by debt leverage ($32.60B total debt) and M&A dilution. This is algorithmic model output, not personal investment advice.
Is ABT stock a buy?
The TradeMates model verdict for ABT is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.